A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

BACKGROUND: The cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors. DESIGN: FOLFIRI + flavopiridol were administered every 2 weeks. Based on sequence-de...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Dickson, Mark A., Shah, Manish A., Rathkopf, Dana, Tse, Archie, Carvajal, Richard D., Wu, Nian, Lefkowitz, Robert A., Gonen, Mithat, Cane, Lauren M., Dials, Heather J., Schwartz, Gary K.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2957673/
https://ncbi.nlm.nih.gov/pubmed/20953860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1269-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki